Alkem Labs - On Growth Path Despite High Base Of Past Year: Motilal Oswal
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Alkem Laboratories Ltd. is well-placed to benefit from a medium-term recovery in the domestic formulation business.
It had a positive impact of higher offtake of Covid-19 associated drugs in the recent past.
The reduction in Covid-19 cases, coinciding with seasonal change, bodes well for a pick-up in the performance of acute therapies.
Bunched-up abbreviated new drug application launches over the next 12-15 months are expected to improve sales growth as well as profitability of the U.S. business.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.